UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (date of earliest event reported):
February 1, 2005
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
Michigan
(State or other jurisdiction of
incorporation) | | 0-22025
(Commission File No.) | | 94-3096597
(I.R.S. Employer Identification
No.) |
24 Frank Lloyd Wright Drive
P.O. Box 376
Ann Arbor, Michigan 48106
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(734) 930-5555
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events.
On February 1, 2005 Aastrom Biosciences, Inc. announced that its US clinical trial for the treatment of long-bone, severe fractures had successfully achieved the first FDA-required clinical benchmark, meeting the clinical safety endpoint for this product when used in bone graft indications. Aastrom is now able to expand this trial to include a broader range of fracture indications. The press release announcing this milestone is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
| | | | | |
| Exhibit No. | | Description |
| | |
| | 99.1 | | | Press release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 1, 2005
| | | | | |
| | AASTROM BIOSCIENCES, INC.
| |
| | By: | /s/ Alan M. Wright | |
| | | Alan M. Wright | |
| | | Senior Vice President, Administrative and
Financial Operations, CFO | |
| |
2
